Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Kim, Bo W ^a,c   Cho, Hanbyoul ^b   Chung, Joon Yong ^a   Conway, Catherine ^a   Ylaya, Kris ^a   Kim, Jae Hoon ^b   Hewitt, Stephen M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c Korea Cancer Center Hospital   (South Korea)

Author keywords

Automated digital image analysis; c Met; Cervical cancer; HIF 1 ; Prognosis

Indexed keywords

CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; AUTOMATION; CANCER PROGNOSIS; CARCINOMA IN SITU; CELL METABOLISM; CONTROLLED STUDY; DIGITAL IMAGING; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RISK ASSESSMENT; SURVIVAL RATE; TUMOR CELL; TUMOR HYPOXIA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTIGENS, NEOPLASM; AUTOMATION; CARBONIC ANHYDRASES; CARCINOMA IN SITU; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84881160120     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-185     Document Type: Article

References (44)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in, GLOBOCAN 2008. Int J Cancer 2008, 2010(127):2893-2917.
2. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999, 15:551-578. 10.1146/annurev.cellbio.15.1.551, 10611972.
3. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med (Berl) 2007, 85:1301-1307.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
5. Kitajima Y, Ide T, Ohtsuka T, Miyazaki K. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci 2008, 99:1341-1347. 10.1111/j.1349-7006.2008.00828.x, 18422749.
6. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007, 26:319-331. 10.1007/s10555-007-9062-2, 17458507.
7. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275. 10.1038/20459, 10353251.
8. Milani M, Harris AL. Targeting tumour hypoxia in breast cancer. Eur J Cancer 2008, 44:2766-2773. 10.1016/j.ejca.2008.09.025, 18990559.
9. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974. 10.1038/nature04483, 16355214.
10. Brahimi-Horn MC, Pouyssegur J. Oxygen, a source of life and stress. FEBS Lett 2007, 581:3582-3591. 10.1016/j.febslet.2007.06.018, 17586500.
11. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Buerger H. HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005, 5:84. 10.1186/1471-2407-5-84, 1190162, 16035955.
12. Hedley D, Pintilie M, Woo J, Morrison A, Birle D, Fyles A, Milosevic M, Hill R. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 2003, 9:5666-5674.
13. Grunkin M, Raundahl J, Foged NT. Practical considerations of image analysis and quantification of signal transduction IHC staining. Methods Mol Biol 2011, 717:143-154. 10.1007/978-1-61779-024-9_8, 21370029.
14. Stromberg S, Bjorklund MG, Asplund C, Skollermo A, Persson A, Wester K, Kampf C, Nilsson P, Andersson AC, Uhlen M, et al. A high-throughput strategy for protein profiling in cell microarrays using automated image analysis. Proteomics 2007, 7:2142-2150. 10.1002/pmic.200700199, 17549799.
15. Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 2006, 48:258-267. 10.1111/j.1365-2559.2005.02322.x, 16430472.
16. Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med 2009, 7:25. 10.1186/1479-5876-7-25, 2672079, 19366452.
17. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007, 60:1112-1116. 10.1136/jcp.2006.044537, 2014838, 17182662.
18. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005, 113:678-682. 10.1002/ijc.20598, 15455388.
19. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007, 67:1670-1679. 10.1158/0008-5472.CAN-06-1147, 17308108.
20. Tsai HW, Chow NH, Lin CP, Chan SH, Chou CY, Ho CL. The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Hum Pathol 2006, 37:198-204. 10.1016/j.humpath.2005.10.012, 16426920.
21. Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A, Raval R, O'Brien TS, Maxwell PH. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006, 66:3567-3575. 10.1158/0008-5472.CAN-05-2670, 16585181.
22. Shimabukuro K, Ichinose S, Koike R, Kubota T, Yamaguchi M, Miyasaka M, Aso T. Hepatocyte growth factor/scatter factor is implicated in the mode of stromal invasion of uterine squamous cervical cancer. Gynecol Oncol 2001, 83:205-215. 10.1006/gyno.2001.6347, 11606073.
23. Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Miyazaki K. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol 2007, 14:2600-2607. 10.1245/s10434-007-9435-3, 17534684.
24. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?. Biochim Biophys Acta 2009, 1795:162-172. 2670353, 19344680.
25. Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 2007, 18:1437-1446. 10.1091/mbc.E06-07-0593, 1838986, 17301289.
26. Yildirim H, Kockar F. TGF-beta upregulates tumor-associated carbonic anhydrase IX gene expression in Hep3B cells. Cell Biol Int 2009, 33:1002-1007. 10.1016/j.cellbi.2009.05.005, 19540352.
27. Baykal C, Ayhan A, Al A, Yuce K, Ayhan A. Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol Oncol 2003, 88:123-129. 10.1016/S0090-8258(02)00073-2, 12586590.
28. Leo C, Horn LC, Einenkel J, Hentschel B, Hockel M. Tumor hypoxia and expression of c-met in cervical cancer. Gynecol Oncol 2007, 104:181-185. 10.1016/j.ygyno.2006.07.040, 16996116.
29. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000, 60:4693-4696.
30. Mayer A, Wree A, Hockel M, Leo C, Pilch H, Vaupel P. Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res 2004, 64:5876-5881. 10.1158/0008-5472.CAN-03-3566, 15313932.
31. Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, Harris AL, Stratford IJ, Price PM, West CM. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004, 10:8405-8412. 10.1158/1078-0432.CCR-03-0135, 15623619.
32. Kim JY, Shin HJ, Kim TH, Cho KH, Shin KH, Kim BK, Roh JW, Lee S, Park SY, Hwang YJ, Han IO. Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J Cancer Res Clin Oncol 2006, 132:302-308. 10.1007/s00432-005-0068-2, 16416108.
33. Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbridge EJ. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010, 116:452-458. 10.1016/j.ygyno.2009.10.062, 2822024, 19913895.
34. Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Fujikawa H, Matsushita K, Uchida K, Inoue Y, Kusunoki M. Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today 2012, 42:460-469. 10.1007/s00595-011-0027-2, 22072148.
35. Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, Messinis IE, Koukoulis G. Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer 2008, 8:335. 10.1186/1471-2407-8-335, 2651893, 19014607.
36. Koukourakis MI, Giatromanolaki A, Polychronidis A, Simopoulos C, Gatter KC, Harris AL, Sivridis E. Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Sci 2006, 97:582-588. 10.1111/j.1349-7006.2006.00220.x, 16827797.
37. Dimitrakoudis D, Ramlal T, Rastogi S, Vranic M, Klip A. Glycaemia regulates the glucose transporter number in the plasma membrane of rat skeletal muscle. Biochem J 1992, 284(Pt 2):341-348. 1132643, 1534653.
38. Hewitt SM, Lewis FA, Cao Y, Conrad RC, Cronin M, Danenberg KD, Goralski TJ, Langmore JP, Raja RG, Williams PM, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2008, 132:1929-1935.
39. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001, 61:1830-1832.
40. Lu ZH, Wright JD, Belt B, Cardiff RD, Arbeit JM. Hypoxia-inducible factor-1 facilitates cervical cancer progression in human papillomavirus type 16 transgenic mice. Am J Pathol 2007, 171:667-681. 10.2353/ajpath.2007.061138, 1934541, 17600126.
41. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000, 14:34-44. 316350, 10640274.
42. Walker F, Kermorgant S, Darai E, Madelenat P, Cremieux AC, Henin D, Lehy T. Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus. Clin Cancer Res 2003, 9:273-284.
43. Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, Henin D, Lehy T, Aparicio T. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol 2009, 40:1517-1527. 10.1016/j.humpath.2009.05.010, 19716155.
44. Nakhleh RE, Grimm EE, Idowu MO, Souers RJ, Fitzgibbons PL. Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med 2010, 134:728-734.